Press release - May 28th, 2009
Dr. Andreas Hartlep is the new Chief Technology Officer at cerbomed
Erlangen, May 28th, 2009. cerbomed gmbh, a start-up company in the area of neurostimulation, announced today that Dr. Andreas Hartlep will take on the position as Chief Technology Officer (CTO).
Dr. Andreas Hartlep brings more than 10 years experience from different management positions in research and development, as well as clinical operations associated with medical engineering, to this leading role. Before his last position as an Executive Director of R&D at Prosurgics, a London-based start-up in image controlled robotics, he was the Director of Clinical Operations at Timaq Medical Imaging, an innovative Swiss consultancy specializing in imaging solutions for pharmaceutical and medical-technology companies. Before this, Dr. Hartlep worked for more than seven years as Research Director at BrainLab, where among other duties, he was responsible for setting up the unit for image-controlled interstitial infusion.
"In Dr. Andreas Hartlep, we have got ourselves an outstanding technology manager with whom we will succeed to guide our innovation in transcutaneous vagus nerve stimulation (t-VNS) to market maturity," says Christoph Bally, Chief Executive Officer (CEO) of the company. He ideally complements the existing business management team of Christoph Bally and the two company founders Dr. Stefan Dietrich and Timo Freitag.
Dr. Andreas Hartlep studied at the universities of Kiel and Heidelberg and graduated in physics and medical physics. He got his Ph.D. (Dr.rer. nat.) at the German cancer research centre (DKFZ) in Heidelberg. After his interdisciplinary professional experience in the areas of medical engineering and neuroscience, the 43-year-old inhabitant of Munich is already looking forward to his new tasks: "I see a huge potential in cerbomed’s innovation, which can lower the suffering of patients with neuropsychiatric illnesses."
cerbomed is a young, medical device company focusing on the research, development and manufacturing of innovative technologies and products in the area of neurostimulation. Its major proprietary procedure, transcutaneous vagus nerve stimulation (t-VNS), will offer a new, alternative treatment for various neuropsychiatric disorders with clinical benefit and improved quality of life at a superior cost benefit ratio.
Since its foundation in December 2005, cerbomed has received many innovation and new enterprise prices (including university- and chamber of commerce new enterprise awards), and was among the federal winners of the German new enterprise prize in 2006.